A newly identified peptide called CI5 from Cinobufacini injection significantly reduced inflammatory pain and swelling in mice by blocking the ERK1/2/COX-2 signaling pathway.
ERK1/2/COX-2 pathwayThe inflammatory signaling cascade that CI5 suppresses by targeting upstream Rac-2 protein
What the researchers found
The peptide CI5, isolated from Cinobufacini injection, demonstrated significant analgesic and anti-inflammatory effects in multiple mouse models. It relieved pain in the acetic acid writhing test and formalin inflammatory pain model, and prevented carrageenan-induced paw edema.
Mechanistically, CI5 reduced levels of key inflammatory markers (IL-6, TNF-α, IL-1β, and PGE2). LC-MS/MS analysis revealed that CI5 exerts its effects by binding to the Rac-2 protein, which sits upstream of the ERK1/2/COX-2 inflammatory signaling axis — the same pathway targeted by common NSAIDs like ibuprofen.
Why it matters
Chronic inflammatory pain remains difficult to treat without side effects from existing drugs. Identifying a natural peptide that targets the same COX-2 pathway as NSAIDs but through a different upstream mechanism could lead to new pain treatments with potentially fewer gastrointestinal and cardiovascular side effects.
How the study worked
Researchers isolated the CI5 peptide from Cinobufacini injection and tested it in three mouse pain/inflammation models: the acetic acid writhing test, the formalin inflammatory pain model, and carrageenan-induced paw edema. They measured inflammatory cytokine levels and used LC-MS/MS proteomics to identify the molecular target and signaling pathway.
What this study cannot tell us
All experiments were conducted in mice, and results may not translate to humans. The study did not compare CI5's efficacy to established analgesics like NSAIDs or opioids. Dosing, pharmacokinetics, and potential toxicity in higher organisms were not evaluated. The specific structure and stability of CI5 as a therapeutic candidate need further characterization.
How to read the evidence
This is a preclinical animal study using established pain and inflammation models in mice. While the mechanistic characterization is thorough, human relevance remains to be established through clinical trials.
When this study was published
Published in 2024 in International Immunopharmacology, this is a recent discovery that adds to the pipeline of peptide-based analgesic candidates.
The bigger picture
Animal venoms and traditional medicines have long been sources of bioactive peptides — ziconotide (from cone snails) is already an FDA-approved pain drug. This study continues that tradition by identifying a specific peptide component responsible for the analgesic effects of a traditional Chinese medicine, opening a path toward targeted drug development.
Questions still open
- How does CI5's analgesic potency compare to existing pain medications like ibuprofen or morphine?
- Would CI5 have fewer gastrointestinal side effects than traditional COX-2 inhibitors since it acts upstream via Rac-2?
- Can CI5 be synthesized or modified for improved stability and oral bioavailability?
Common questions
What is Cinobufacini injection?
How is this different from regular anti-inflammatory drugs?
Read the original research
Novel analgesic peptide derived from Cinobufacini injection suppressing inflammation and pain via ERK1/2/COX-2 pathway.
International immunopharmacology, 141, 112918
Citation
Guo, Li; Zhang, Sai; Zhang, Cong; Ren, Shuang; Zhou, Zihan; Wang, Fengyuan; Wang, Yuexuan; Chen, Qiqi; Wang, Yubing; Lee, Wen-Hui; Zhu, Kui; Qin, Di; Gao, Yuanyuan; Sun, Tongyi. (2024). Novel analgesic peptide derived from Cinobufacini injection suppressing inflammation and pain via ERK1/2/COX-2 pathway.. International immunopharmacology, 141, 112918. https://doi.org/10.1016/j.intimp.2024.112918